← Back to Journals

NATURE REVIEWS DRUG DISCOVERY

Publisher:
Springer Nature
ISSN:
1474-1776
Category:
PHARMACOLOGY & PHARMACY
Impact factor:
122.7
Official website ↗Official RSS source ↗

Feed status

38 parsed articles

Last update: 2026-09-22

Latest articles

The evolving landscape of drug targets

2026-09-21

Liliana Halip, Sorin Avram, John P. Overington, Bissan Al-Lazikani, Ramona Curpan, Suman Sirimulla, Alexei Pushechnikov, Andrea Rosario Beccari, Nikolay Savchuck, Tudor I. Oprea

Advances in areas including genomics, automation and data science, as well as the diversification of therapeutic modalities, have led to a substantial expansion of the drug target landscape in the past 25 years. This Review maps and quantifies key elements of these changes, and discusses trends in the number and type of targets through which drugs mediate their therapeutic effects, which now include ~700 biomolecules.

DOI: 10.1038/s41573-026-01530-3

A translational framework for extrahepatic oligonucleotide delivery

2026-09-09

Łukasz Jan Kiełpiński, Felix Franz Schumacher

To unlock the ‘plug-and-play’ potential of extrahepatic delivery of oligonucleotide-based drugs, the field must bridge the gap between preclinical promise and clinical reality. Here, we outline an industry-grade quality framework to eliminate methodological artifacts and ensure the translational and commercial viability of novel platforms.

DOI: 10.1038/d41573-026-00125-2

Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus

2026-06-04

Jean B. Nachega

Nature Reviews Drug Discovery, Published online: 04 June 2026; doi:10.1038/d41573-026-00094-6 The ongoing outbreak of Bundibugyo Ebola virus disease in the Democratic Republic of the Congo highlights the urgent need to bridge therapeutic gaps for non-Zaire ebolaviruses by prioritizing and accelerating development and evaluation of broadly applicable and species-specific filovirus countermeasures.]]>

DOI: 10.1038/d41573-026-00094-6

Targeting claudins in cancer

2026-05-28

Yuki Niwa

Nature Reviews Drug Discovery, Published online: 28 May 2026; doi:10.1038/s41573-026-01450-2 Claudins are emerging as clinically actionable targets in cancer, exemplified by the approval of CLDN-18.2-directed therapy. This review examines the biological basis and therapeutic exploitation of claudins, highlighting diverse targeting modalities and the shift towards leveraging tight junction components as tumour-selective entry points for precision oncology strategies.]]>

DOI: 10.1038/s41573-026-01450-2

Realizing the potential of agonistic antibody immunotherapy

2026-05-19

Mark S. Cragg

Nature Reviews Drug Discovery, Published online: 19 May 2026; doi:10.1038/s41573-026-01442-2 Agonistic antibodies initiate signalling by the receptors they target, mimicking the activities of native ligands. This Review discusses the clinical successes and failures of agonistic antibodies and explains how recent mechanistic insights should broaden the scope and improve the safety and efficacy of immunotherapies based on these agents.]]>

DOI: 10.1038/s41573-026-01442-2